Vimarsana
Biggest News Aggregation in the World

Page 29 - William Doyle News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from William Doyle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In William Doyle Today - Breaking & Trending Today

Maryland's port director resigned after a car crash involving state vehicle - Vimarsana News

Maryland's port director resigned after a car crash involving state vehicle

The head of the Maryland Port Administration has resigned, after being involved in a four-vehicle crash last week that resulted in state police citing him with leaving the scene. Maryland

Source: wvnews.com
TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC - Vimarsana News

TTFields With SOC Shows Clinically Meaningful Overall Survival Improvement in Metastatic NSCLC

The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).

Source: ajmc.com
Protect Digital Assets From The Threat Of Supercomputers: Q&A With ... - Vimarsana News

Protect Digital Assets From The Threat Of Supercomputers: Q&A With ...

Protect Digital Assets From The Threat Of Supercomputers: Q&A With ...

Tumor Treating Fields With Standard of Care May Significantly Improve Survival in Metastatic NSCLC - Vimarsana News

Tumor Treating Fields With Standard of Care May Significantly Improve Survival in Metastatic NSCLC

Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.

TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy - Vimarsana News

TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy

The addition of tumor treating fields to standard-of-care immunotherapy or chemotherapy regimens elicited an improvement in overall survival vs SOC therapies alone in patients with metastatic non-small cell lung cancer following progression on or after platinum-based chemotherapy, according to data from the phase 3 LUNAR trial.